Background: Patients with severe cervical multilevel stenosis and an adequate lordotic curvature often undergo multilevel laminectomies with posterior instrumented fusions. Although the "gold standard" for the fusion mass remains iliac crest autograft, many require additional volume provided by bone graft expanders. Here, we studied the fusion rates for 32 patients undergoing multilevel cervical laminectomy and vertex/rod/eyelet/titanium cable fusions utilizing lamina/iliac autograft and the bone graft expander Nanoss (RTI Surgical, Alachua, FL, USA) with autogenous bone marrow aspirate (BMA). Methods: Thirty-two patients, averaging 63.0 years of age, presented with severe cervical myeloradiculopathy (average Nurick Grade 4.4). Magnetic resonance (MR) studies documented 2-3-level high intrinsic cord signals, whereas computed tomography (CT) scans confirmed marked stenosis and ossification of the posterior longitudinal ligament (OPLL)/ossification of the yellow ligament (OYL). Patients underwent multilevel lamnectomies/instrumented fusions, and were followed up for an average of 2.7 years. Results: Multilevel laminectomies (2.8 levels) and average 7.8-level vertex/rod/ eyelet/cable fusions were performed utilizing lamina/iliac crest autograft and Nanoss/BMA. Fusion was confirmed on X-ray/CT studies an average of 4.7 months postoperatively in 31 of 32 patients (97%); there was just one pseudarthrosis requiring secondary surgery. The only other complication was a delayed transient C5 palsy that fully resolved in 6 postoperative months. Conclusions: Thirty-two severely myelopathic underwent 2.8-level cervical laminectomies/7.8 level fusions utilizing lamina/iliac autograft and Nanoss/BMA. Fusion was documented on both dynamic X-ray and CT studies in 31 of 32 (97%) patients an average of 4.7 months postoperatively. Nanoss/BMA appears to be a safe and effective bone graft expander that can be utilized for posterior cervical fusions.
INTRODUCTION
Following multilevel cervical laminectomies/posterior fusions, the volume of iliac crest autograft (e.g., the "gold standard") may require supplementation with a bone graft expander. Although there are many types available here we prospectively performed 32 multilevel level cervical laminectomies/posterior instrumented fusions (vertex/rod/ eyelet/titanium cable) utilizing lamina/iliac crest autograft supplemented with Nanoss (RTI Surgical Alachua, FL, USA) and autologous bone marrow aspirate (BMA). Over an average of 2.7 postoperative years, we utilized both dynamic X-ray and computed tomography (CT) studies to assess fusion rates.
MATERIALS AND METHODS
Prospectively, 32 patients averaging 63 years of age presented with severe cervical myeloradiculopathy (average Nurick Grade 4.4) [ Table 1 ]. Marked focal stenosis was documented on both magnetic resonance (MR) and computed tomographic (CT) studies along with ossification of the posterior longitudinal ligament (OPLL) and/or ossification of the yellow ligament (OYL) [ Figures 1-4 Fusion technique/mass: Vertex/rod/eyelet fusion, autograft, and Nanoss/BMA
The vertex/rod/eyelet/titanium cable system was applied to the intact spinous processes cephalad/caudad to the laminectomy levels [ Figure 5 ]. Ten cc of BMA, collected during the iliac crest autograft harvesting, was then immediately applied to the 2.5 cm. × 10 cm Nanoss strips. The laminae and facet joints were then decorticated cephalad/caudad to the laminectomy levels; at the laminectomy levels, only the very lateral residual laminae/facets were decorticated. Lamina and iliac crest autograft (morcellized with a rongeur/but not turned into a paste with the bone mill) were applied over the decorticated surfaces, the largest volumes being placed where the laminae were intact, whereas only the smallest cancellous bone fragements were applied laterally at the laminectomy sites. Finally, Nanoss/BMA strips were placed dorsal to the autograft; ¼ inch strips over the intact laminar levels, but just 1/8 th inch strips laterally at the laminectomy levels.
RESULTS
Cervical surgery required an average of 4.6 hours. Patients underwent average 2.8-level cervical 
Avoidance of infections
No patient developed an infection. The avoidance of infections was largely attributed to the use of Hibiclens washes started 2 weeks preoperatively, the intraoperative use of antibiotic irrigation every 15 minutes, the use of postoperative prophylactic antibiotics, and utilizing a Silverlon dressing for up to 1 month postoperatively on the posterior cervical wound. 
DISCUSSION
Iliac crest autograft (the "gold standard") with Nanoss/BMA Iliac crest autograft is still considered the "gold standard" for a fusion mass. Nevertheless, when the autograft fusion mass is insufficient, Nanoss provides a Food and Drug Administration (FDA) approved bone void filler/expander (e.g., approved for posterolateral spinal fusions) when combined with laminar/iliac autograft and BMA. Nanoss, composed of nanostructured hydroxyapatite (HA), is an engineered extracellular osteoconductive bioscaffold matrix that facilitates cell infiltration. In this study, we confirmed the efficacy of Nanoss/BMA in promoting a 97% posterior cervical fusion rate. In several prior studies, Nanoss was found to be comparable to Vitoss (Stryker, Kalamazoo, MI, USA).
Safety/efficacy of Vitoss, and Vitoss vs. Nanoss in Lumbar Spine Fusion
The safety and efficacy of Vitoss and Vitoss vs. Nanoss as bone graft expanders were documented in prior studies of the lumbar spine. In 2006, Epstein utilized Vitoss and lamina autograft (50:50 mix) to perform 40 laminectomies (average 3.7 levels), and 1 (27 patients) and 2 (13 patients) level posterolateral instrumented pedicle/screw fusions. [2] At 6 postoperative months, dynamic X-rays and CT studies confirmed fusion for 26 of 27 single-level fusions, and 11 of 13 two-level fusions; only 1 of the latter patients with symptomatic pseudarthrosis required secondary surgery. In a review of the literature in 2008, Epstein found similar fusion rates and outcomes for noninstrumented vs. instrumented lumbar fusions utilizing demineralized bone matrix (DBMs)/allografts, hydroxyapatite (HA), and Beta TriCalcium Phosphate (B-TCP: Vitoss). [3] In 2015, performed an initial comparison of the efficacy of Vitoss (213 patients) vs. Nanoss (45 patients) in promoting posterolateral lumbar noninstrumented fusions. [7] Patients underwent comparable multilevel lumbar laminectomies (average 4.6 vs. 4.5 levels, respectively), and noninstrumented fusions (average 
Safety/efficacy of Vitoss and Vitoss vs. Nanoss in Cervical Spine Fusion
The safety and efficacy of Vitoss and Vitoss vs. Nanoss as bone graft expanders were also previously documented in the cervical spine. In 2008, Epstein evaluated the fusion rates for 35 severely myelopathic adults (mean Nurick Grade 4.1) undergoing average 2-level laminectomies with average 7-level posterior cervical vertex/rod eyelet/braided titanium cable fusions utilizing lamina/iliac autograft and Vitoss/BMA. [4] For these adults averaging 65 years of age, 100% fusion was documented on both dynamic X-rays and CT studies an average of 5.2 months postoperatively. Complications included 2 transient root injuries (transient C5 palsies in diabetic patients that spontaneously resolved), 2 wound infections, 1 wound breakdown, no pseudarthroses, no reoperations, no cord injuries, and no mortalities. In 2011, Epstein next reviewed 53 severely myelopathic patients averaging 65.3 years of age undergoing cervical laminectomies (average 2.3 levels) and instrumented fusions (average 7.5 levels) again utilizing iliac crest autograft and B-TCP/Vitoss. [5] Fusion occurred on X-ray studies (100%) and 2D-CT studies (86.8% of patients) an average of 5.4 months postoperatively; 3 smokers demonstrated delayed fusions at 8 postoperative months. In 2015, comparing two successive cohorts, Epstein preliminarily confirmed the efficacy of Vitoss (72 patients) vs. Nanoss (20 patients) (RTI: Alachua, FL, USA) as bone graft expanders for posterior cervical fusions (vertex/rod/eyelet/braided titanium cables). [6] Fusion was respectively documented an average of 5.65 vs. 5.35 months postoperatively utilizing both dynamic X-ray and CT studies. There were 2 cases of pseudarthrosis among the 72 fused with Vitoss vs. none in the 20 patients receiving Nanoss/BMA. Notably, in the present study, 31 of 32 (97%) patients fused utilizing lamina/iliac crest autograft and Nanoss/BMA fused on postoperative dynamic-ray/CT studies obtained an average of 4.7 months postoperatively.
Other bone graft expanders Bone morphogenetic protein, demineralized bone matrix, and ceramics
Other bone graft expanders/supplements, including bone morphogenetic protein [BMP: Infuse; Medtronic, Memphis, USA)], demineralized bone matrix (DBM), and ceramics, have promoted spinal fusions. BMP promoted fusions even without autograft; however, several authors were concerned about observed/ anticipated complications (e.g. heterotopic ossification, osteolysis, postoperative seromas, increased infection, and increased cancer rates). [1, 9, 10] In 2013, Grabowski and Cornett acknowledged that, although iliac crest bone graft remained the "gold standard," multiple different bone graft substitutes (BMP, DBM, other graft expanders/allograft) were increasingly in use. [9] They too noted the: "recent concern regarding their safety (BMP) has tempered enthusiasm regarding their use." In 2015, Bauman et al. studied 101 posterolateral thoracolumbar instrumented fusions (PLF) addressing traumatic vertebral fractures. [1] The fusion rates for both groups were nearly comparable; 94% with DBM/PLF (16 patients) and 100% with autograft/PLF (46 patients). The complication rates were also similar for both groups; 1 deep infection in the DBM group and 2 superficial wound infections in the autograft bone group (ABG) group. In 2016, using Medline, Kadam et al. identified 181 clinical studies that utilized BMP (62 studies, 34.25%), ceramics (40 studies), and allografts (39 studies) as bone graft expanders spinal fusions. [10] Although clinical outcomes were comparable in all groups, the best fusion rates were obtained utilizing BMP, followed by allograft, and lastly DBM.
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